BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38114711)

  • 1. Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer.
    Anderson JN; Paladino AJ; Blue R; Dangerfield DT; Eggly S; Martin MY; Schwartzberg LS; Vidal GA; Graetz I
    J Cancer Surviv; 2023 Dec; ():. PubMed ID: 38114711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
    Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
    JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
    Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
    BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
    Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
    Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
    Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
    J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncologists' perspectives on adherence/non-adherence to adjuvant endocrine therapy and management strategies in women with breast cancer.
    Eraso Y
    Patient Prefer Adherence; 2019; 13():1311-1323. PubMed ID: 31534318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
    Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
    Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
    Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
    Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
    Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
    Toledo G; Ochoa CY; Farias AJ
    Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Nobody Will Tell You. You've Got to Ask!": An Examination of Patient-Provider Communication Needs and Preferences among Black and White Women with Early-Stage Breast Cancer.
    Anderson JN; Graff JC; Krukowski RA; Schwartzberg L; Vidal GA; Waters TM; Paladino AJ; Jones TN; Blue R; Kocak M; Graetz I
    Health Commun; 2021 Oct; 36(11):1331-1342. PubMed ID: 32336140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors.
    Sutton AL; Salgado TM; He J; Hurtado-de-Mendoza A; Sheppard VB
    Support Care Cancer; 2020 Sep; 28(9):4147-4154. PubMed ID: 31897782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Lambert LK; Balneaves LG; Howard AF; Gotay CC
    Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of Adjuvant Therapy Attitudes in African American Breast Cancer Patients.
    Edmonds MC; Sutton AL; He J; Perera RA; Sheppard VB
    J Natl Med Assoc; 2020 Apr; 112(2):167-175. PubMed ID: 32197898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of an Information Leaflet to Influence Medication Beliefs in Women With Breast Cancer: A Randomized Factorial Experiment.
    Green SMC; Hall LH; French DP; Rousseau N; Parbutt C; Walwyn R; Smith SG
    Ann Behav Med; 2023 Oct; 57(11):988-1000. PubMed ID: 37494669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acceptability, fidelity and trial experience of four intervention components to support medication adherence in women with breast cancer: A process evaluation protocol for a pilot fractional factorial trial.
    Green SMC; Hall LH; Rousseau N; French DP; Graham CD; Collinson M; Mason E; Wilkes H; Howdon D; Foy R; Walwyn R; Clark J; Parbutt C; Raine E; Ellison R; Buxton J; Moore SJL; Velikova G; Farrin A; Smith SG
    NIHR Open Res; 2023; 3():3. PubMed ID: 37881449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management.
    Samuel CA; Turner K; Donovan HAS; Beckjord E; Cardy A; Dew MA; van Londen GJ
    Support Care Cancer; 2017 Dec; 25(12):3723-3731. PubMed ID: 28681126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study.
    Gagné M; Lauzier S; Lemay M; Loiselle CG; Provencher L; Simard C; Guillaumie L
    Support Care Cancer; 2022 Jun; 30(6):4759-4768. PubMed ID: 35133477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer.
    Paladino AJ; Anderson JN; Krukowski RA; Waters T; Kocak M; Graff C; Blue R; Jones TN; Buzaglo J; Vidal G; Schwartzberg L; Graetz I
    BMC Health Serv Res; 2019 Dec; 19(1):977. PubMed ID: 31856812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.